Cancer cachexia: drugs in the patent literature

Bibliography

• Bossola M, Pacelli F, Doglietto GB. Novel treatments for cancer cachexia. Expert Opin Investig Drugs 2007;16:1241-53
   PubMed Web of Science ®Google Scholar
• Laviano A, Meguid MM, Rossi Fanelli F. Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol 2003;4:686-94
   PubMed Web of Science ®Google Scholar
• Dempsey DT, Knox LS, Mullen JL, et al. Energy expenditure in malnourished patients with colorectal cancer. Arch Surg 1996;121:789-95
   Google Scholar
• Gibney E, Elia M, Jebb SA, et al. Total energy expenditure in patients with non small-cell lung cancer: results of a validated study using the bicarbonate-urea method. Metabolism 1997;46:1412-7
   PubMed Web of Science ®Google Scholar
• Todorov P, Cariuk P, Mc Devitt T, et al. Characterization of a cancer cachectic factor. Nature 1996;379:739-42
   PubMed Web of Science ®Google Scholar
• Costelli P, Tullio RD, Baccino FM, et al. Activation of Ca(2+)-dependent proteolysis in skeletal muscle and heart in cancer cachexia. Br J Cancer 2001;84:946-50
   PubMed Web of Science ®Google Scholar
• Costelli P, Baccino FM. Mechanisms of skeletal muscle depletion in wasting syndromes: role of ATP-ubiquitin-dependent proteolysis. Curr Opin Clin Nutr Metab Care 2003;6:407-12
   PubMed Web of Science ®Google Scholar
• Bossola M, Muscaritoli M, Costelli P, et al. Increased muscle ubiquitin mRNA levels in gastric cancer patients. Am J Physiol Regul Integr Comp Physiol 2001;280:R1518-23
   PubMed Web of Science ®Google Scholar
• Bossola M, Muscaritoli M, Costelli P, et al. Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. Ann Surg 2003;237:384-9
   PubMed Web of Science ®Google Scholar
• Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001;294:1704-8
   PubMed Web of Science ®Google Scholar
• Acharyya S, Guttridge DC. Cancer cachexia signalling pathways continue to emerge yet much still points to the proteasome. Clin Cancer Res 2007;13:1356-61
   PubMed Web of Science ®Google Scholar
• Guttridge DC, Mayo MW, Madrid LV, et al. NF-kappa B-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000;289:2363-6
   PubMed Web of Science ®Google Scholar
• Costelli P, Muscaritoli M, Bossola M, et al. Skeletal muscle wasting in tumour-bearing rats is associated with MyoD down-regulation. Int J Oncol 2005;26:1663-8
   PubMedGoogle Scholar
• Penna F, Reffo P, Sonetto A, et al. Myostatin expression is up-regulated in cancer cachexia. 27th Congress of the European Society of Clinical Nutrition and Metabolism (ESPEN). Brussels, 27 – 30 August 2005 (Abstract P299)
   Google Scholar
• Lopez AP, Roque Figuls M, Cuchi GU, et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Sympt Manag 2004;27:360-9
   PubMed Web of Science ®Google Scholar
• Jatoi A, Windschiltl HE, Loprinzi CL, et al. Dronabinol versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment study. J Clin Oncol 2002;20:567-73
   PubMed Web of Science ®Google Scholar
• Strasser F, Luftner D, Possinger K, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome. A multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 2006;24:3394-400
   PubMed Web of Science ®Google Scholar
• Baldwin C, Parsons T, Logan S. Dietary advice for illness-related malnutrition in adults. Cochrane Database Syst Rev 2001;2:CD002008
   Google Scholar
• Milne AC, Potter J, Avenell A. Protein and energy supplementation in elderly people at risk of malnutrition. Cochrane Database Syst Rev 2002;3:CD003288
   Google Scholar
• Mirhosseini N, Fainsinger RL, Baracos V. Parenteral nutrition in advanced cancer: indications and clinical practice guidelines. J Pall Med 2005;8:914-8
   PubMedGoogle Scholar
• American Society For Parenteral And Enteral Nutrition Board Of Directors. Guidelines for the use of parenteral and enteral nutrition in adult pediatric patients. J Parenter Enteral Nutr 2002;26:SA1-138
   Google Scholar
• Arends J, Bodoky G, Bozzetti F, et al. ESPEN guidelines on enteral nutrition: non-surgical oncology. Clin Nutr 2006;25:245-59
   PubMed Web of Science ®Google Scholar
• Whitehouse AS, Smith HJ, Drake JL, et al. Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid. Cancer Res 2001;61:3604-9
   PubMed Web of Science ®Google Scholar
• Wigmore SJ, Barber MD, Ross JA. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer 2000;36:177-84
   PubMed Web of Science ®Google Scholar
• Jatoi A, Kendrith R, Loprinzi CL, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both in patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 2004;22:2469-76
   PubMed Web of Science ®Google Scholar
• Fearon KC, Barber MD, Moses AG, et al. Double-blind, placebo controlled, randomised study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 2006;24:3401-7
   PubMed Web of Science ®Google Scholar
• Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neuroscience 2005;8:571-8
   PubMed Web of Science ®Google Scholar
• Kask A, Rago L, Mutulis F, et al. Selective antagonist for the melanocortin-4 receptor (HS014) increases food intake in free-feeding rats. Biochem Biophys Res Commun 1998;245:90-3
   PubMedGoogle Scholar
• Huszar D, Lynch CA, Fairchild-Huntress V, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997;88:131-41
   PubMed Web of Science ®Google Scholar
• Marks DL, Cone RD. The role of the melanocortin-3 receptor in cachexia. Ann NY Acad Sci 2003;994:258-66
   PubMed Web of Science ®Google Scholar
• Marks DL, Ling N, Cone RD. Role of the central melanocortin system in cachexia. Cancer Res 2001;61:1432-8
   PubMed Web of Science ®Google Scholar
• Small CJ, Liu Y, Stanley SA, et al. Chronic CNS administration of Agouti-related protein (Agrp) reduces energy expenditure. Int J Obesity 2003;27:530-3
   PubMed Web of Science ®Google Scholar
• Vergoni AV, Bertolini A, Wikberg JES, Schioth HB. Selective melanocortin MC4 receptor blockage reduces immobilization stress-induced anorexia in rats. Eur J Pharmacol 1999;369:11-5
   PubMedGoogle Scholar
• Wisse BE, Frayo RS, Schwartz MW, Cummings DE. Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 2001;142:3292-301
   PubMed Web of Science ®Google Scholar
• Vos TJ, Caracoti A, Che JL, et al. Identification of 2-[2-[2-(5-bromo-2-methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole (ML00253764), a small-molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model. J Med Chem 2004;47:1602-4
   PubMed Web of Science ®Google Scholar
• Nicholson JR, Kohler G, Schaerer F, et al. Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of a lean body mass in tumor-bearing mice. J Pharmacol Exp Ther 2006;317:771-7
   PubMed Web of Science ®Google Scholar
• Tucci FC, White NS, Markison S, et al. A potent and orally active nonpeptide antagonist of the human melanocortin-4 receptor based on a series of trans-2-disubstituted cyclohexypiperazines. Bioorg Med Chem Lett 2005;15:4389-95
   PubMedGoogle Scholar
• Markison S, Foster AC, Chen C, et al. The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist. Endocrinology 2005;146:2766-73
   PubMed Web of Science ®Google Scholar
• Chen CW, Tran JA, Jiang W, et al. Propionylpiperazines as human melanocortin-4 receptor ligands. Bioorg Med Chem Lett 2006;16:4800-3
   PubMedGoogle Scholar
• Chen C, Jang W, Tucci F, et al. Discovery of 1-[2-[(1S)-(3-dimethylaminopropionyl)amino-2-methylpropyl]-4-methylphenyl]-4-[(2R)-methyl-3-(4-chlorophenyl)-propionyl]piperazine as an orally active antagonist of the melanocortin-4 receptor for the potential treatment of cachexia. J Med Chem 2007;50:5249-52
   PubMedGoogle Scholar
• Tran JA, Jang W, Tucci F, et al. Design, synthesis, in vitro, and in vivo characterization of phenylpiperazines and pyridinylpiperazines as potent and selective antagonists of the melanocortin-4 receptor. J Med Chem 2007;50:6356-66
   PubMed Web of Science ®Google Scholar
• Jiang J, Tucci FC, Tran JA, et al. Pyrrolididones as potent functional antagonists of the human melanocortin-4 receptor. Bioorg Med Chem Lett 2007;17:5610-3
   PubMed Web of Science ®Google Scholar
• Neurocrine Biosciences, Inc. MXPA04011093; 2005
   Google Scholar
• Markison S, Foster AC, Chen C, et al. The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist. Endocrinology 2005;146:2766-73
   PubMed Web of Science ®Google Scholar
• Vos TJ, Balani S, Blackburn C, et al. Identification and structure-activity relationships of a new series of Melanocortin-4 receptor antagonists. Bioorg Med Chem Lett 2006;16:2302-5
   PubMed Web of Science ®Google Scholar
• Gene Logic, Inc. US20070878708; 2007
   Google Scholar
• Poitout L, Brault V, Sackur C, et al. Identification of a novel series of benzimidazoles as potent and selective antagonists of the human melanocortin-4 receptor. Bioorg Med Chem Lett 2007;17:4464-70
   PubMedGoogle Scholar
• Sod Conseils Rech. Applic. FR20030013988; 2003
   Google Scholar
• Nozawa D, Okubo T, Chaki S, et al. Identification of arginine analogues as antagonists and agonists for the melanocortin-4 receptor. Chem Pharm Bull 2007;55:1232-9
   PubMedGoogle Scholar
• Arasasingham PN, Fotsch C, Ouyang X, et al. Structure-activity relationship of (1-aryl-2-piperazinylethyl)piperazines: antagonists for the AGRP/melanocortin receptor binding. J Med Chem 2003;46:9-11
   PubMed Web of Science ®Google Scholar
• Taisho Pharmaceutical Co., Ltd. JP20010389419; 2001
   Google Scholar
• Nozawa D, Okubo T, Ishii T. Structure-activity relationships of novel piperazines as antagonists for the melanocortin-4 receptor. Bioorg Med Chem 2007;15:1989-2005
   PubMedGoogle Scholar
• Santhera Pharmaceuticals Schwe. EP20030006256; 2003
   Google Scholar
• Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656-60
   PubMed Web of Science ®Google Scholar
• Hanada T, Toshinai K, Kajimura N, et al. Anticachectic effect of ghrelin in nude mice bearing human melanoma cells. Biochem Biophys Res Commun 2003;301:275-9
   PubMed Web of Science ®Google Scholar
• Deboer MD, Zhu XX, Levasseur P, et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology 2007;148:3004-12
   PubMed Web of Science ®Google Scholar
• Nagaya N, Uematsu M, Kojima M, et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 2001;104:1430-5
   PubMed Web of Science ®Google Scholar
• Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Endocrinol Metab 2001;86:5992-5
   PubMed Web of Science ®Google Scholar
• Schmid DA, Held K, Ising M, et al. Ghrelin stimulates appetite, imagination of food, GH, ACTH, and cortisol, but does not affect leptin in normal controls. Neuropsychopharmacology 2005;30:1187-92
   PubMed Web of Science ®Google Scholar
• Druce MR, Neary NM, Small CJ, et al. Subcutaneous administration of ghrelin stimulates energy intake in healthy lean human volunteers. Int J Obesity 2006;30:293-6
   Web of Science ®Google Scholar
• Nagaya N, Itoh T, Murakami S, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest 2005;128:1187-93
   PubMed Web of Science ®Google Scholar
• Wynne K, Giannitsopoulou K, Small CJ, et al. Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial. J Am Soc Nephrol 2005;16:2111-8
   PubMed Web of Science ®Google Scholar
• Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrin Metab 2004;89:2832-6
   PubMed Web of Science ®Google Scholar
• Mintz L. US2007238662; 2007
   Google Scholar
• Cheng K, Chan WW, Butler B, et al. A novel non-peptidyl growth hormone secretagogue. Horm Res 1993;40:109-15
   PubMedGoogle Scholar
• Xin Z, Zhao H, Serby MD, et al. Synthesis and structure-activity relationships of isoxazole carboxamides as growth hormone secretagogue receptor antagonists. Bioorg Med Chem Lett 2005;15:1201-4
   PubMed Web of Science ®Google Scholar
• Liu G. US20040797734; 2004
   Google Scholar
• Langer CJ, Hoffman JP, Ottery FD, et al. Clinical significance of weight loss in cancer patients: rationale for the use of anabolic agents in the treatment of cancer-related cachexia. Nutrition 2001;17(Suppl):S1-20
   PubMed Web of Science ®Google Scholar
• Sheffield Moore M. Androgens and the control of skeletal muscle protein synthesis. Ann Med 2000;32:181-6
   PubMed Web of Science ®Google Scholar
• Demling RH, Desanti L. Oxandrolone induced lean mass gain during recovery from severe burns is maintained after discontinuation of the anabolic steroid. Burns 2003;29:793-7
   PubMed Web of Science ®Google Scholar
• Earthman CP, Reid PM, Harper IT, et al. Body cell mass repletion and improved quality of life in HIV-infected individuals receiving oxandrolone. J Parenter Enteral Nutr 2002;26:357-65
   PubMed Web of Science ®Google Scholar
• Creutzberg EC, Wouters EF, Mostert R, et al. A role for anabolic steroids in the rehabilitation of patients with COPD? A double-blind, placebo-controlled, randomized trial. Chest 2003;104:1733-42
   Google Scholar
• Chlebowski RT, Herrold J, Ali I, et al. Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer. Cancer 1986;58:183-6
   PubMed Web of Science ®Google Scholar
• Tchekmedyian S, Fesen M, Price LM, et al. Ongoing placebo-controlled study of oxandrolone in cancer-related weight loss. Int J Radiat Oncol Biol Phys 2003;57(Suppl):S283-4
   Google Scholar
• Kilbourne EJ, Moore WJ, Freedman LP, et al. Selective androgen receptor modulators for frailty and osteoporosis. Curr Opin Invest Drugs 2007;8:821-9
   PubMedGoogle Scholar
• Gao W, Dalton JT. Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov Today 2007;12:241-8
   PubMed Web of Science ®Google Scholar
• Dalton JT, Mukherjee A, Zhu Z, et al. Discovery of nonsteroidal androgens. Biochem. Biophys Res Commun 1998;244:1-4
   PubMed Web of Science ®Google Scholar
• Edwards JP, West SP, Pooley CL, et al. New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone. Bioorg Med Chem Lett 1998;8:745-50
   PubMed Web of Science ®Google Scholar
• Miner JN, Chang W, Chapman MS, et al. An orally-active selective androgen receptor modulator is efficacious on bone, muscle and sex function with reduced impact on prostate. Endocrinology 2006;148:363-73
   PubMedGoogle Scholar
• Yin D, Gao W, Kearby JD, et al. Pharmacodynamics of selective androgen receptor modulators. J Pharmacol Exp Ther 2003;304:1334-40
   PubMed Web of Science ®Google Scholar
• Gao W, Reiser PJ, Coss CC, et al. Selective androgen receptor modulator (SARM) treatment improves muscle strength and body composition, and prevent bone loss in orchidectomized rats. Endocrinology 2005;146:4887-96
   PubMed Web of Science ®Google Scholar
• Gao W, Kearbey JD, Nair VA, et al. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5 alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. Endocrinology 2004;145:5420-8
   PubMed Web of Science ®Google Scholar
• Ostrowski J, Kuhns JE, Lupisella JA, et al. Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology 2007;148:4-12
   PubMed Web of Science ®Google Scholar
• Hanada K, Furuya K, Yamamoto N, et al. Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biol Pharm Bull 2003;26:1563-9
   PubMed Web of Science ®Google Scholar
• Merck & Co, Inc. WO2003US08277; 2007
   Google Scholar
• Merck & Co, Inc. US. US20040623442P; 2004
   Google Scholar
• Merck & Co, Inc. US. US20070712727; 2007
   Google Scholar
• Merck & Co, Inc. US20040576335; 2004
   Google Scholar
• Ng RA, Guan J, Alford VC Jr, et al. 2-(2,2,2-Trifluoroethyl)-5,6-dichlorobenzimidazole derivatives as potent androgen receptor antagonists. Bioorg Med Chem Lett 2007;17:955-88
   PubMed Web of Science ®Google Scholar
• Ng RA, Guan J, Alford VC Jr, et al. Synthesis and SAR of potent and selective androgen receptor antagonists: 5,6-dichloro-benzimidazole derivatives. Bioorg Med Chem Lett 2007;17:784-8
   PubMedGoogle Scholar
• Ng RA, Lanter JC, Alford VC, et al. Synthesis of potent and tissue-selective androgen receptor modulators (SARMs): 2-(2,2,2)-trifluoroethyl-benzimidazole scaffold. Bioorg Med Chem Lett 2007;17:1784-7
   PubMedGoogle Scholar
• Janssen Pharmaceutica NV. US2006116412; 2006
   Google Scholar
• Allan GF, Tannenbaum P, Sbriscia T, et al. A selective androgen receptor modulator with minimal prostate hypertrophic activity enhances lean body mass in male rats and stimulates sexual behavior in female rats. Endocrine 2007;32:41-51
   PubMed Web of Science ®Google Scholar
• Piu F, Gardell LR, Son T, et al. Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator. J Steroid Biochem Mol Biol 2008109:129-137
   PubMed Web of Science ®Google Scholar
• Higuchi RI, Arienti KL, López FJ, et al. Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. J Med Chem 2007;50:2486-96
   PubMed Web of Science ®Google Scholar
• Higuchi RI, Thompson AW, Chen JH, et al. Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones. Bioorg Med Chem Lett 2007;17:5442-6
   PubMedGoogle Scholar
• Janssen Pharmaceutica NV. US2005014952; 2005
   Google Scholar
• Janssen Pharmaceutica NV. US2006063819; 2006
   Google Scholar
• Janssen Pharmaceutica NV. US20040628337P; 2006
   Google Scholar
• Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors. Cell 1995;83:841-50
   PubMed Web of Science ®Google Scholar
• Allergan Sales, Inc. US20060348520; 2006
   Google Scholar
• Univ. Boston. US2003166159; 2003
   Google Scholar
• Takashiba S, Van Dyke TE, Shapira L, et al. Lipopolysaccharide-inducible and salicylate-sensitive nuclear factor(s) on human tumor necrosis factor alpha promoter. Infect Immun 1995;63:1529-34
   PubMed Web of Science ®Google Scholar
• Polyak K, Xia Y, Zweier JL, et al. A model for p53-induced apoptosis. Nature 1997;389:300-5
   PubMed Web of Science ®Google Scholar
• Pfizer. MX9603975; 1997
   Google Scholar
• Pfizer. US19940310171; 1994
   Google Scholar
• Wagner G, Laufer S. Small molecular anti-cytokine agents. Med Res Rev 2006;26:1-62
   PubMed Web of Science ®Google Scholar
• Snow Brand Milk Prod. Co., Ltd. JP19970082162; 1998
   Google Scholar
• Daiichi Seiyaku, Co. US2003236191; 2003
   Google Scholar
• Lazzarino DA, Diego M, Musi E, et al. CXCR4 and CCR5 expression by H9 T-cells is downregulated by a peptide-nucleic acid immunomodulator. Immunol Lett 2000;74:189-95
   PubMed Web of Science ®Google Scholar
• Lazzarino DA, De Diego M, Hirschman SZ, et al. IL-8 and MCP-1 secretion is enhanced by the peptide-nucleic acid immunomodulator, Product R, in U937 cells and primary human monocytes. Cytokine 2001;14:234-9
   PubMed Web of Science ®Google Scholar
• Advanced Viral Res. Corp. US6303153; 2001
   Google Scholar
• Advanced Viral Res. Corp. US6528098; 2002
   Google Scholar
• Advanced Viral Res. Corp. CA2611087; 2006
   Google Scholar
• Stahl SM. Basic psychopharmacology of antidepressants, part 1: antidepressants have seven distinct mechanisms of action. J Clin Psychol 1998;59:5-14
   Google Scholar
• Haddjeri N, Blier P, De Montigny C. Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. J Pharm Exp Ther 1996;277:861-71
   PubMed Web of Science ®Google Scholar
• Univ. South Florida. WO200100196; 2001
   Google Scholar
• Kast RE, Foley KF. Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care 2007;16:351-4
   PubMed Web of Science ®Google Scholar
• Davis MP, Khawam E, Pozuelo L, Lagman R. Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. A World Health Organization project. Exp Rev Anticancer Ther 2002;2:365-76
   PubMedGoogle Scholar
• Passik SD, Lundberg J, Kirsh KL, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Sympt Manag 2002;23:526-32
   PubMed Web of Science ®Google Scholar
• Strasser F, Lutz TA, Maeder MT, et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer 2008;98:300-8
   PubMed Web of Science ®Google Scholar
• Garcia JM, Garcia-Touza M, Hijazi RA, et al. Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab 2005;90:2920-6
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Nagaya N, Isobe T, et al. Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res 2003;9:774-8
   PubMed Web of Science ®Google Scholar